SCHEDULE: Vanguard Group Reports 0% Stake in Rigel Pharma
Beneficial Ownership Update
The Vanguard Group reported a 0% beneficial ownership in Rigel Pharmaceuticals Inc. following an internal corporate realignment.
Summary
- The Vanguard Group reported 0.00 shares beneficially owned in Rigel Pharmaceuticals Inc. Common Stock.
- This represents 0% of the class of securities.
- The change is attributed to an internal realignment within The Vanguard Group, Inc. on January 12, 2026.
- Following the realignment, certain subsidiaries or business divisions will report beneficial ownership separately, disaggregated from The Vanguard Group, Inc.
- The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative update regarding The Vanguard Group's internal structure, not reflecting a change in investment sentiment towards Rigel Pharmaceuticals Inc.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding Rigel Pharmaceuticals Inc.'s future performance or The Vanguard Group's investment strategies beyond the reporting realignment.
Industry Context
StockSavvy.ai notes that such internal realignments by large asset managers like The Vanguard Group are operational and administrative in nature. They typically reflect changes in internal reporting structures rather than a fundamental shift in investment thesis or a divestment based on the underlying company's performance, such as Rigel Pharmaceuticals Inc.
Stakeholder Impact
- Shareholders of Rigel Pharmaceuticals Inc. should understand that this filing reflects an administrative change in how The Vanguard Group reports its beneficial ownership, not necessarily a complete divestment of all underlying holdings by Vanguard's managed funds. The actual investment exposure of Vanguard's clients to Rigel Pharmaceuticals Inc. may remain through separately reporting subsidiaries.
Key Dates
| Date | Description |
|---|---|
| 01/12/2026 | Internal realignment within The Vanguard Group, Inc. occurred, leading to disaggregated reporting by subsidiaries. |
| 03/13/2026 | Date of event which required the filing of this statement. |
| 03/27/2026 | Date the Schedule 13G/A filing was signed by The Vanguard Group. |
Keywords
Rigel Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, Equity Stake, Internal Realignment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.